Replies to post #2278 on BioCurex, Inc.(fka BOCX)

[Kag]

Please ask Dr. Moro if he believes Abbott's first serum RECAF cancer screening test, that Abbott is implementing into its Architect system, will likely require a premarketing approval (PMA) from the FDA. If he indicates that it may require a PMA, also ask if the test could still be ready for market within the 12 to 18 month timeframe that was indicated in the July 2005 Research Notes. Thanks, kag

[HALF FULL GLASS]

earthang,

I would like to see a monthly update from Biocurex. This would inform current investors as well as gather enthusiasm from potential new investors. Obviously we would like to hear about progress from Goshen, Abbott, additional licensing partners. Although I believe these are in progress, As far as we know right now all of these leads could be sitting in someones in box. Obviously this information would need to come out via a news update so that there are no problems with insider info. That is the last thing we need right now.

I thought it was very smart of Biocurex to post the last news with an eye catching header but then direct the persons to the Biocurex board to read the news.

This method allows persons to get more familiar/educated with the company by bringing them to the web site.

[Kag]

Erthang,
I have a humble suggestion to make. When I have talked to a CEO on the phone, I found it difficult to concentrate on their responses, and at the same time, take good notes. It will help to use a speaker phone, and have another person write notes on the responses too. I appreciate what you doing, and also the offer to ask our questions too. Thanks, kag

[mysscat]

Let's see: When will we get off pinks? When is the annual letter coming out? Great idea to keep investors apprised monthly of what's happening with company, even if it is "we're still waiting to hear from Abbott". I truly believe that the stock price keeps dropping because there is such a lag between press releases. They've got to be learning something every month. I saw the stock GMED.pk published the results of just one person taking their drug in a press release and the stock went up more than it has in ages. Other companies are using press releases to keep the company's name out there. BOCX seems not to care, or to be too afraid to put anything in writing. It scares investors.

[great-grandma]

Good luck, erthang, and thanks for doing this. I myself am most concerned with the timeline for getting RECAF to market and for getting off the pinks. Thanks again.